0001437749-26-012393
SEC filingCatheter Precision, Inc. held a Special Meeting of stockholders on April 15, 2026, where six proposals related to preferred stock conversions, conversion price adjustments, and a potential reverse stock split were approved by majority vote.
The approval of all six proposals signals significant corporate action enabling future capital structure flexibility and potential equity dilution management. Proposals 1–4 collectively authorize issuance of new common stock tied to multiple series of convertible preferred stock, which may facilitate financing execution or investor liquidity events upon conversion. Proposal 4’s approval specifically permits additional shares due to a reduction in the Series B preferred stock conversion price — a structural change that increases potential dilution unless offset by concurrent share repurchases or performance-based triggers not disclosed herein. Proposal 5’s authorization of a discretionary reverse stock split (1-for-2 to 1-for-100) grants the board authority to adjust share count without further shareholder approval, potentially aimed at satisfying exchange listing requirements or improving perceived marketability; however, no timing, ratio selection, or implementation plan is disclosed. The absence of broker non-votes on Proposals 5 and 6 indicates broad support among registered holders and suggests alignment between management and major investors on strategic governance tools. With only 49.5% of outstanding shares represented, the approvals reflect consent from a minority of total equity but meet statutory voting thresholds under Delaware law and the Company’s charter as referenced in the proxy statement.